The NGS, dPCR, and ARMS techniques have demonstrated high accuracy in detecting KRAS mutation in LB samples and could be used to guide anti-EGFR therapy in CRC patients without available tumor tissue samples [106]. This evidence concerns the gene KRAS and colorectal carcinoma.